At Janssen, our core responsibility is to develop innovative treatments for unmet medical needs and delivering great outcomes to patients and society. To strengthen our efforts, we collaborate with many other groups and organisations who share the same goal. With our pharmaceutical expertise, we play a vital role in advancing medicine, through research and development of new treatments, as well as ongoing education and continued safety monitoring. Collaboration, mutual trust and respect are essential for bringing value to both patients and society.
At Janssen, we work in trusted partnerships with patient organisations, and healthcare professionals to help transform lives and reinvent healthcare. Since the 13th of January 2020, Janssen Sciences Ireland UC have introduced a 'legitimate interest' model to disclose any payments made to healthcare professionals (HCPs), and healthcare organisations (HCOs) with whom we work.
The way we collaborate with HCPs is governed first by law and further by industry standards set out by the Irish Pharmaceutical Healthcare Association (IPHA) code of practice. In addition, Janssen has its own ethical business principles for our collaboration with HCPs, “The Janssen Way”. Integrity in working with the medical community and HCPs
Janssen is publicly disclosing any Transfers of Value (ToV) Janssen has made to HCPs and HCOs as required by the IPHA Code.
The ToV’s to be disclosed can be categorised into three key areas:
Janssen sponsors and supports where possible Continuous Professional Development (CPD) programmes (i.e. congresses, educational meetings, etc.) in order to further educate HCPs about new treatment approaches, and in doing so, enhance their knowledge for the benefit of their patients.
We aim to provide fair and balanced education programmes that follow guidelines defined by accrediting bodies in Europe; these are based on the medical community’s educational needs and are carried out by independent expert committees.
At Janssen, our support of educational programmes is regulated and transparent:
Logistical arrangements for these activities follow Irish Pharmaceutical Healthcare Association (IPHA) guidelines, are always modest and strictly limited to the HCPs and to the main purpose of the event.
Medical advances, pharmaceutical innovation and the expansion of treatment options for many diseases would not be possible without the above-described collaboration with HCPs and HCOs. In taking new steps to increase transparency, we are aiming to show that this collaboration is legitimate and with the purpose of improving patient outcomes. We feel strongly that the pharmaceutical industry and the medical community have a collective responsibility to explain this to society and to ensure this collaboration continues for the future.
CP-229344 | April 2021